Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice
- 31 August 2015
- journal article
- research article
- Published by Wiley in BioFactors
- Vol. 41 (5) , 324-329
Abstract
Dystrophin lack in DMD causes neuronal nitric oxide synthase (nNOS) membrane delocalization which in turn promotes functional muscle ischemia, and exacerbates muscle injury. Apoptosis and the exhaustion of muscle regenerative capacity are implicated in Duchenne muscular dystrophy (DMD) pathogenesis and therefore are relevant therapeutic targets. Genistein has been reported to have pro‐proliferative effects, promoting G1/S cell phase transition through the induction of cyclin D1, and anti‐apoptotic properties. We previously showed that genistein could reduce muscle necrosis and enhance regeneration with an augmented number of myogenin‐positive satellite cells and myonuclei, ameliorating muscle function in mdx mice. In this study we evaluated the underlying mechanisms of genistein effect on muscle specimens of mdx and wild type mice treated for five weeks with genistein (2 mg/kg/i.p. daily) or vehicle. Western blot analysis show that genistein increased cyclin D1 and nNOS expression; and showed an antiapoptotic effect, modulating the expression of BAX and Bcl‐2. Our results suggest that this isoflavone might enhance the regenerative spurt in mdx mice muscle restoring nNOS, promoting G1/S phase transition in muscle cell, and inhibiting apoptosis. Further studies with longer time treatment or using different experimental approaches are needed to better investigate the underlying mechanisms of such results. © 2015 BioFactors, 41(5):324–329, 2015Keywords
This publication has 41 references indexed in Scilit:
- The Steady-State Serum Concentration of Genistein Aglycone Is Affected by Formulation: A Bioequivalence Study of Bone ProductsBioMed Research International, 2012
- Reduced chondrocyte proliferation, earlier cell cycle exit and increased apoptosis in neuronal nitric oxide synthase-deficient miceOsteoarthritis and Cartilage, 2012
- Nitric Oxide Sustains Long-Term Skeletal Muscle Regeneration by Regulating Fate of Satellite Cells Via Signaling Pathways Requiring Vangl2 and Cyclic GMPStem Cells, 2012
- Co‐administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humansBritish Journal of Pharmacology, 2010
- Nitric oxide inhibition of Drp1-mediated mitochondrial fission is critical for myogenic differentiationCell Death & Differentiation, 2010
- Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophyHuman Molecular Genetics, 2009
- Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophyJournal of Clinical Investigation, 2009
- Enhanced Na+/H+ Exchange Activity Contributes to the Pathogenesis of Muscular Dystrophy via Involvement of P2 ReceptorsThe American Journal of Pathology, 2007
- Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapyProceedings of the National Academy of Sciences, 2007
- Selectivity and potency of cyclin-dependent kinase inhibitorsThe AAPS Journal, 2006